What Johnson & Johnson’s Alios Acquisition Means for Gilead Sciences

RBC Capital Market’s Michael Yee and team look at what Johnson & Johnson’s (JNJ) acquisition of Alios BioPharma means for Gilead Sciences (GILD): Johnson & Johnson announced an agreement to acquire Alios BioPharma for $1.75B in cash. We generally agree that the deal was in good part for its respiratory syncytial virus (RSV) drug ALS-8176 which [...]